Thomas Wierzba to Enterotoxins
This is a "connection" page, showing publications Thomas Wierzba has written about Enterotoxins.
Connection Strength
0.179
-
Rao MR, Wierzba TF, Savarino SJ, Abu-Elyazeed R, El-Ghoreb N, Hall ER, Naficy A, Abdel-Messih I, Frenck RW, Svennerholm AM, Clemens JD. Serologic correlates of protection against enterotoxigenic Escherichia coli diarrhea. J Infect Dis. 2005 Feb 15; 191(4):562-70.
Score: 0.063
-
Rao MR, Abu-Elyazeed R, Savarino SJ, Naficy AB, Wierzba TF, Abdel-Messih I, Shaheen H, Frenck RW, Svennerholm AM, Clemens JD. High disease burden of diarrhea due to enterotoxigenic Escherichia coli among rural Egyptian infants and young children. J Clin Microbiol. 2003 Oct; 41(10):4862-4.
Score: 0.057
-
Qadri F, Akhtar M, Bhuiyan TR, Chowdhury MI, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Lundgren A, Wiklund G, Kaim J, Löfstrand M, Carlin N, Bourgeois AL, Maier N, Fix A, Wierzba T, Walker RI, Svennerholm AM. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2020 02; 20(2):208-219.
Score: 0.044
-
Clemens J, Savarino S, Abu-Elyazeed R, Safwat M, Rao M, Wierzba T, Svennerholm AM, Holmgren J, Frenck R, Park E, Naficy A. Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method. J Infect Dis. 2004 Jun 15; 189(12):2299-307.
Score: 0.015